{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:31Z","timestamp":1791078871496,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.3816\/clm.2006.n.031","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:17Z","timestamp":1221095417000},"page":"488-492","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Mycosis Fungoides with Denileukin Diftitox and Oral Bexarotene"],"prefix":"10.3816","volume":"6","author":[{"given":"Rakhshandra","family":"Talpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.n.031_bib1","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.031_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","article-title":"Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides","volume":"19","author":"de Coninck","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.031_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/eji.1830200412","article-title":"Interleukin-2 receptor-targeted cytotoxicity: receptor binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells","volume":"20","author":"Waters","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.3816\/CLM.2006.n.031_bib4","first-page":"167","article-title":"Immunotoxin DAB 389 Interleukin-2 (Ontak\u00ae) in the management of cutaneous T-cell lymphoma","volume":"2","author":"Duvic","year":"1999","journal-title":"Curr Pract Med"},{"key":"10.3816\/CLM.2006.n.031_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1998","journal-title":"JAMA"},{"key":"10.3816\/CLM.2006.n.031_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0733-8635(05)70155-8","article-title":"Emerging new therapies for cutaneous T-cell lymphoma","volume":"18","author":"Duvic","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.3816\/CLM.2006.n.031_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/Sezary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib9","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.031_bib11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2006.n.031_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J American Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib13","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.031_bib14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"JAAD"},{"key":"10.3816\/CLM.2006.n.031_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low dose interferon-\u03b1 and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2006.n.031_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.031_bib17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.031_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0889-8588(03)00114-X","article-title":"High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma","volume":"17","author":"Oyama","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2006.n.031_bib19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archderm.138.10.1359","article-title":"Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma","volume":"138","author":"Guitart","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib20","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol (Stockholm)"},{"key":"10.3816\/CLM.2006.n.031_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0190-9622(96)90683-0","article-title":"Photopheresis therapy for cutaneous T cell lymphoma","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 1","key":"10.3816\/CLM.2006.n.031_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000248873","article-title":"Retinoids in cutaneous T cell lymphomas","volume":"175","author":"Mahrle","year":"1987","journal-title":"Dermatologica"},{"key":"10.3816\/CLM.2006.n.031_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000418097","article-title":"Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas","volume":"19","author":"Serri","year":"1990","journal-title":"Curr Probl Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.1988.tb02600.x","article-title":"Treatment of mycosis fungoides with recombinant interferon -alpha 2a alone and in combination with etretinate","volume":"118","author":"Thestrup-Pedersen","year":"1988","journal-title":"B J Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-4362.1993.tb01458.x","article-title":"Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides","volume":"32","author":"Altomare","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1346-8138.1994.tb03285.x","article-title":"Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides","volume":"21","author":"Torii","year":"1994","journal-title":"J Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0190-9622(92)70142-3","article-title":"Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"26","author":"Jones","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2340\/0001555567179182","article-title":"Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.3816\/CLM.2006.n.031_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2340\/0001555562162164","article-title":"Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor in mycosis fungoides","volume":"62","author":"Zachariae","year":"1982","journal-title":"Acta Derm Venereol (Stockholm)"},{"key":"10.3816\/CLM.2006.n.031_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/1076-0512(95)92762-T","article-title":"Etretinate as an effective adjunctive therapy for recalcitrant palmar\/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis","volume":"21","author":"Lim","year":"1995","journal-title":"Dermatol Surg"},{"key":"10.3816\/CLM.2006.n.031_bib32","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon alpha 2a plus acitretin versus interferon alpha 2a plus PUVA in patients with cutaneous T cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.031_bib33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0190-9622(03)02488-5","article-title":"Management of refractory earlystage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy","volume":"50","author":"Huber","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2003.10.669","article-title":"Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms","volume":"50","author":"McGinnis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.031_bib37","first-page":"601a","article-title":"Phase I dose escalation study of Targretin and ONTAK in hematologic malignancies: upregulation of IL2R expression by low dose Targretin","volume":"98","author":"DiVenuti","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.031_bib38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.20009","article-title":"Activity of interferon-alpha and isotretinoin in patients with advanced refractorylymphoid malignancies","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.031_bib39","doi-asserted-by":"crossref","first-page":"723a","DOI":"10.1182\/blood.V104.11.2644.2644","article-title":"Results of a phase II trial of oral bexarotene combined with interferon alfa-2b for patients with cutaneous T-cell lymphoma (CTCL)","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:10:52Z","timestamp":1738361452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S1557919011702827"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.031","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}